IWK Health Centre, Division of Gastroenterology, 5850 University Avenue, Halifax, Nova Scotia, B3J 3G9, Canada.
Expert Rev Clin Immunol. 2005 Jul;1(2):277-92. doi: 10.1586/1744666X.1.2.277.
Complementary and alternative medicine use is increasing in both the general population and in individuals with chronic illness. A significant proportion of adult and pediatric patients with inflammatory bowel disease use or have used complementary and alternative medicine as determined by multiple surveys conducted in North America, Europe and Australia. There was a heterogenous selection of complementary and alternative medicine therapies chosen by patients, with variations due to geography and age. However, in general, their use is sought due to frustration with conventional therapies and the perceived safety of complementary and alternative medicine therapies. One of the dilemmas that arises when assessing the topic of complementary and alternative medicine use is rapidly changing definitions of what is and what is not considered conventional medicine. With our increasing understanding of the intricacies of the gastrointestinal immune system and host-microflora interactions, determining a scientific basis behind many complementary and alternative medicine therapies in vitro or in vivo is leading to evaluation of these therapies in humans. This will require well-designed and rigourously conducted clinical trials with sufficient sample size.
补充和替代医学的应用在普通人群和慢性病患者中都在增加。通过在北美、欧洲和澳大利亚进行的多项调查发现,相当一部分炎症性肠病的成年和儿科患者使用过或正在使用补充和替代医学。患者选择的补充和替代医学疗法具有异质性,因地理位置和年龄的不同而有所不同。然而,一般来说,他们使用补充和替代医学疗法是因为对传统疗法感到沮丧,以及认为补充和替代医学疗法更安全。在评估补充和替代医学使用这一主题时,出现的一个难题是,传统医学的定义在迅速变化,什么是传统医学,什么不是传统医学。随着我们对胃肠道免疫系统和宿主-微生物群相互作用复杂性的认识不断加深,确定许多补充和替代医学疗法在体外或体内的科学基础,正在导致对这些疗法在人类中的评估。这将需要设计良好、严格进行的临床试验,且样本量足够大。